TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides an update on the outstanding […]
Autor: Firma TME Pharma
TME Pharma Announces Successful Advice Meeting With US Food And Drug Administration On NOX-A12 Development In Brain Cancer
Constructive meeting held with FDA provided feedback and clear guidance on key aspects of further development of NOX-A12 combinations for the treatment of glioblastoma Preparatory work on-track to open […]
TME Pharma announces further improvement in median overall survival at 19 months follow-up in GLORIA brain cancer trial
. Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 combination with radiotherapy and bevacizumab Survival rate in this cohort at 19 months is […]
TME Pharma annonce le vif succès de son augmentation de capital avec droits préférentiels de souscription pour un montant de 2,7 millions d’euros
L’opération a permis de lever un montant total de 2,7 millions d’euros et d’émettre 10,8 millions d’actions nouvelles. La demande importante principalement des actionnaires existants s’est élevée à 5 millions […]
TME Pharma announces results of successful capital increase with preferential subscription rights for €2.7 million
Transaction raised the full amount of €2.7 million leading to the issuance of 10.8 million new shares Strong demand primarily from existing shareholders amounted to 5 million shares representing subscription […]
TME Pharma annonce l’ouverture de la cotation des droits préférentiels de souscription pour l’augmentation de capital entièrement garantie de 2,7 millions d’euros
Ces informations ne sont pas destinées aux résidents du Royaume-Uni, des États-Unis, de l’Australie, du Canada ou du Japon. Voir l’annexe pour une clause de non-responsabilité complète. • Le montant […]
TME Pharma announces the initiation of the listing of preferential subscription rights for fully guaranteed €2.7 million capital increase
This information is not intended for residents of the United Kingdom, United States, Australia, Canada or Japan. See Annex for full disclaimer. Guaranteed portion of the transaction will extend cash […]
TME Pharma Launches fully guaranteed €2.7 million preferential rights issue with warrants attached combined with buyback of convertible debt
Guaranteed portion of the transaction will extend cash runway past regulatory milestones in Q1-2024 The financial visibility will allow TME Pharma to file and receive feedback from FDA on its […]
TME Pharma reports H1 2023 financial results and provides business update
Survival data from NOX-A12 GLORIA Phase 1/2 trial in brain cancer continue to improve and have already surpassed all relevant competitors 67% overall survival at 18 months for NOX-A12 […]
Further improvement in overall survival at 18 months to 67% for NOX-A12 combination regimen in brain cancer
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces that another patient has reached […]